A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Preliminary Clinical Activity and Immunogenicity of Multiple Doses of MOR103 Administered Intravenously to Patients With Active Rheumatoid Arthritis.
Phase of Trial: Phase I/II
Latest Information Update: 22 May 2015
At a glance
- Drugs Otilimab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors MorphoSys
- 10 Jun 2017 Biomarkers information updated
- 14 Nov 2012 Results presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.
- 06 Nov 2012 Results will be presented in a late-breaking abstract at the 2012 American College for Rheumatology Annual Meeting, according to a MorphoSys media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History